Life-Changing Medicines.
Redefining Possibilities.
patient story
Journey to Diagnosis
Narcolepsy is a condition that is often misunderstood, overlooked and underdiagnosed. Many people will write off excessive daytime sleepiness in teenagers because it is assumed teenagers want to sleep more often. Sam lived more than a decade experiencing symptoms of narcolepsy without a diagnosis.
Sam’s Story
Our science
Changing AML Treatment Landscape
We’re committed to developing life-changing medicines that can redefine the possibilities for life after a cancer diagnosis — in particular for patients with certain types of secondary acute myeloid leukemia (AML).
Learn More
News and Events
March 20, 2019
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 5, 2019
Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
February 26, 2019
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
As a leader in sleep medicine, we’re committed to increasing awareness of complex diseases within the sleep category.
#SleepAwareness
Month
See all News
Jazz Pipeline
PRE-CLINICAL
Oxybate
once-nightly formulation
CombiPlex
Solid tumors candidate I

CombiPlex
Hem/onc exploratory activities

Asparaginase
ALL/other hematological malignancies
Recombinant Pegaspargase
Hematological
malignancies
Defibrotide
Exploratory activities

Exosome NRAS candidate
Hematologic malignancies§

Exosome STAT3 candidate
Hematologic malignancies§

Exosome-based candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS* (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
CD33+ AML‖

IMGN632
CD123+ hematological malignancies‖

PHASE 2
Solriamfetol
EDS in Parkinson’s disease
Defibrotide
Prevention of acute GvHD
Defibrotide
Treatment of TA-TMA†
Defibrotide
Prevention of CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML*

CPX-351
MDS**†

CPX-351
R/R AML**

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
Prevention of VOD

CPX-351
AML or HR-MDS (AML19) (ages 18-60)**‡

CPX-351
AML or HR-MDS (AML18) (ages ≥60)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy
Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
† Planned
‡Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences collaboration
‖ Jazz & ImmunoGen collaboration

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
More About Jazz
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Our Medicines